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Background and objectives: The American Thoracic Society/European Respiratory Society (ATS/ERS) Task Force
acknowledged the multi-faceted nature of asthma in its recent definition of asthma control as a summary term
capturing symptoms, reliever use, frequency/severity of exacerbations, lung function, and future risk and the Global
Initiative for Asthma (GINA) defines the clinical manifestations (well established markers of asthma severity) of
asthma to include symptoms, sleep disturbances, limitations of daily activity, impairment of lung function, and use
of rescue medications. The objectives of this qualitative work were to identify symptoms and markers of symptom
severity relevant to patients with moderate to severe asthma and to evaluate the content validity of the asthma
symptom diary (ASD).
Methods: A qualitative interview study was conducted using a purposive sample of symptomatic adult and
adolescent (≥12 years) subjects with asthma. Concept elicitation (CE) interviews (n = 50) were conducted to identify
core asthma symptoms and symptom-related clinical markers, followed by cognitive interviews (n = 24) to ensure
patient comprehension of the items, instructions and response options. CE interviews were coded using ATLAS.ti
for content analysis.
Results: The study sample had a diverse range of symptom severity, level of symptom control, sociodemographic
and socioeconomic status. The most frequently reported symptoms in adults were chest tightness (n = 33/34;
97.1%), wheezing (n = 31; 91.2%), coughing (n = 30; 88.2%), and shortness of breath (n = 25; 73.5%); in adolescents
they were wheezing (n = 14/16; 87.5%), coughing (n = 13; 81.3%), and chest tightness (n = 11; 68.8%). Adults identified
chest tightness followed by shortness of breath as their most severe symptoms; while adolescents reported coughing
and chest tightness as their most severe symptoms. Sleep awakenings and limitations in day-to-day activities were
frequent symptom-related clinical markers. Day-to-day variability and differences between daytime and nighttime
symptom experiences reported by subjects resulted in the need for the ASD to be administered twice daily. Cognitive
interviews indicated that subjects found the revised ASD items clear and easy to understand.
Conclusions: This study supports the content validity of the revised ASD, showing it to be consistent with patient
experiences and ready for further psychometric testing.
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Asthma is a serious, highly prevalent disease which
affects all age groups, with an estimated 1 in 13 people
affected in the United States (US) [1]. Globally, 300
million people suffer from asthma with 250,000 deaths
attributable to asthma each year [2] and a prevalence of
8.2% which has increased annually between 2001 and
2009 at a rate of 1.2% [3]. With around 12.8 million
people (8.7 million adults and 4 million children (aged
0–17)) having an attack within the last year, resulting in
10.5 million missed school days and 14.2 million missed
work days in 2008 [3], asthma has a significant societal
impact and is a serious public health problem [4].
Airflow limitation measured by forced expiratory vol-
ume in one second (FEV1), has been, and still is, an im-
portant endpoint used in asthma clinical trials [5,6].
However, there is growing recognition that traditional
clinical outcomes, such as lung function, are inadequate
indicators of how asthma patients function and feel [7].
The multifactorial and complex nature of asthma control
[8] is supported by evidence indicating poor correlations
between lung function and symptoms and between lung
function and ß-agonist usage [9,10].
The American Thoracic Society/European Respiratory
Society (ATS/ERS) Task Force acknowledged the multi-
faceted nature of asthma in its recent definition of
asthma control as a summary term capturing symptoms,
reliever use, frequency/severity of exacerbations, lung
function, and future risk [5] and the Global Initiative for
Asthma (GINA) defines the clinical manifestations (well
established markers of symptom severity) of asthma to
include symptoms, sleep disturbances, limitations of
daily activity, impairment of lung function, and use of
rescue medications [4].
Clinicians tend to underestimate asthma symptom se-
verity, making the use of a patient-completed daily diary
for the assessment of asthma symptoms and markers of
symptom severity in clinical trials essential [11-13]. As
identified by the National Institutes of Health (NIH)
Asthma Outcomes Workshop [14] and further confirmed
by an internally conducted focused literature review, there
is no current asthma diary that can be recommended for
use due to the lack of published validation data or appro-
priate recall period.
The Asthma Control Questionnaire (ACQ) is widely
regarded as a useful measure that includes some core
asthma symptoms and symptom-related clinical markers
of asthma. While the ACQ is designated as a core meas-
ure in NIH-initiated clinical research [8], the seven-day
recall period represents a potential shortcoming in the
context of FDA recommendations for symptom mea-
sures in clinical trials [15]. Given the variable nature of
asthma symptoms, a measure with a shorter recall
(i.e., daily), is preferable. Also, while self-reported use ofrescue medication is important to capture, its incorpor-
ation into a symptom scale may introduce some limita-
tion in symptom scale interpretation (i.e., to what extent
do changes in the symptom score simply reflect changes
in rescue medication use rather than reflecting a true
change in symptoms).
Prior to the Food and Drug Administration (FDA)
Guidance for PROs, Amgen had developed an electronic
patient-reported outcome (ePRO) diary to assess asthma
symptoms and rescue medication use on a daily basis.
Following the publication of the FDA Guidance, it was
recognized that the measure required additional study to
evaluate and document its content validity [16,17]. Follow-
ing the recommendations in the FDA guidance, qualitative
patient interviews were conducted to elicit relevant con-
cepts. Subsequently, cognitive interviews were conducted
to assess patient comprehension of the concepts presented
by the diary items. As the measure under development
was intended to be a daily diary, the team, comprising
clinical and PRO measurement experts, decided that
capturing the broader range of asthma impacts was not
feasible. However, as reflected in the literature [18] the ef-
fect on sleep and activities are key markers of symptom
severity. Therefore a decision was made that, if supported
by patient qualitative research, these two items would be
retained (at least in the qualitative phase of study) as
markers of symptom severity.
This work aimed to evaluate the content validity of the
asthma symptom diary (ASD) for use as an efficacy end-
point in asthma clinical trials to support labelling claims.
This article describes the qualitative research phase
documenting content validity in adult and adolescent
asthma patients, and the resulting revisions. The evalu-
ation of the cross-sectional measurement properties of
the ASD, conducted subsequent to the qualitative re-
search, will be reported elsewhere [19].
Methods
Concept elicitation interviews (n = 50) and cognitive in-
terviews (n = 24) were conducted in adults and adolescent
(≥12 years) who had a clinical diagnosis of persistent
asthma. Four sites, asthma care clinical practices, in differ-
ent regions of the US were used to recruit patients for the
interviews. Institutional Review Board (Essex IRB Inc.) ap-
proval was obtained prior to study initiation.
Subjects
Subjects were screened for eligibility, enrolled, and sched-
uled for one of the two types of qualitative interviews. In-
cluded subjects had an asthma diagnosis for at least one
year, were on asthma treatment maintenance medication
regimen, and were either non-smokers or ex-smokers
(<10 pack years and stopped ≥1 year ago). Subjects were
not included if they had any major health problems
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consent. Additionally, the study was designed to ensure
that patient clinical and demographic characteristics were
similar to those to be included in the planned clinical trial
program.
Study measures
As part of the enrollment process, patients completed
a self-administered version of the Asthma Control
Questionnaire (ACQ-7) and the Asthma Quality of
Life Questionnaire (AQLQ).
The ACQ-7 [20] is a seven-item instrument assessing
asthma control during the past week. The ACQ includes
six patient-reported items about nighttime awakening,
symptom severity upon awakening, activity limitation
due to asthma, shortness of breath due to asthma,
wheezing, and use of a short-acting bronchodilator. The
final item is the forced expiratory volume in one second
(FEV1) % predicted completed by clinicians following
spirometry. Items are scored 0 (good control) to 6 (poor
control), and the total ACQ score is the mean of the
seven items.
AQLQ12+ (12 years and older) [21] contains 32 items
comprising four domains: Activity Limitation, Asthma
Symptoms, Emotional Function, and Environmental
Stimuli. Items are scored 1 (severe impairment) to 7 (no
impairment), with domain scores calculated as the mean
of the items within each domain; the overall AQLQ12+
score is the mean of all 32 items.
Clinical and sociodemographic forms
Clinicians provided additional descriptive information
from the patient records and subjects completed a socio-
demographic form that included patients’ date of birth,
gender, race/ethnicity, years of education, employment
status, and income level.
Concept elicitation interviews
The first phase of the qualitative work consisted of indi-
vidual concept elicitation interviews with 34 adults and
16 adolescent subjects having a diagnosis of asthma.
Each face-to-face individual interview was conducted
privately and lasted approximately 60 minutes. The
semi-structured interview guide asked patients to de-
scribe their experience with asthma symptoms and
symptom related impacts during a typical day. Rating ex-
ercises for symptom bothersomeness and degree of diffi-
culty patients experienced in coping with their asthma
were conducted at the end of each interview. Interview
results were used to identify the most relevant concepts
to the patient experience, and the predominant termin-
ology used by patients in identifying their asthma symp-
toms and impacts.Following the concept elicitation interviews an
item generation meeting was convened to review the
qualitative data and revise and/or create new items to
the existing items in the earlier diary. This meeting was
attended by clinical experts in the treatment of asthma,
PRO development experts, and members of the sponsor’s
team.Cognitive interviews
The cognitive interviews were subsequently conducted in
15 adults and 9 adolescents to assess the patients’ com-
prehension of the items, the clarity of response options,
and the overall feasibility of the measure (format, instruc-
tions, appropriate attribution, and language) in the
revised version of the ASD. The cognitive interviews
were conducted in an iterative process using three waves
with evaluation and revision of the diary items following
each wave of interviews.Analysis
All interviews were digitally recorded and then tran-
scribed. ATLAS.ti software was used to organize the
codes being assigned to the transcript data. Descriptive
statistics from screening and enrollment data were used
to further describe the study population.
A concept saturation table was used to identify the point
at which no new concepts were being identified in the
data. The transcripts were ordered chronologically based
on interview date, and grouped into quartiles. The codes
of each subsequent transcript group were compared with
those from the prior group. If new codes appeared in
subsequent group, it would suggest that saturation had
not been achieved.
Translatability (cross-cultural applicability) and read-
ing comprehension level (lexibility) assessments were
conducted. All alterations made to the ASD items
throughout the process were recorded in an item track-
ing matrix.Results
Sociodemographic and clinical characteristics
Sociodemographic and clinical characteristics are out-
lined in Tables 1 and 2. The sample reflects diversity in
terms of disease severity, gender, age (both adults and
adolescents), education, ethnicity, and socioeconomic
status, and was aimed to reflect the general asthma
population. Disease control, as defined by ACQ score,
was broad (ranging from 0.14-3.8) in order to ensure
that the ASD items would be suitable for use across
patients with the full spectrum of controlled and uncon-
trolled asthma.
Table 1 Demographic characteristics of study subjects
Concept elicitation interviews Cognitive interviews
Adult N = 34 (100%) Adolescent N = 16 (100%) Adult N = 15 (100%) Adolescent N = 9 (100%)
Age (years):
Mean (SD) 38.9 (13.0) 15.2 (1.6) 30.7 (9.7) 14.1 (2.2)
Gender:
Male 13 (38.2%) 9 (56.3%) 2 (13.3%) 7 (77.8%)
Female 21 (61.8%) 7 (43.8%) 13 (86.7%) 2 (22.2%)
Marital status:
Married or living as married 14 (41.2%) — 5 (33.3%) —
Widowed 1 (2.9%) — 1 (6.7%) —
Divorced 5 (14.7%) — 2 (13.3%) —
Never married 14 (41.2%) 16 (100.0%) 7 (46.7%) 9 (100.0%)
Education*:
Elementary school — 6 (37.5%) 2 (13.3%) 6 (66.7%)
High school 3 (8.8%) 10 (62.5%) 1 (6.7%) 3 (33.3%)
College 29 (85.3%) — 10 (66.7%) —
Graduate or professional school 2 (5.9%) — 2 (13.3%) —
Employment outside home:
Full-time 18 (52.9%) — 7 (46.7%) —
Part-time 8 (23.5%) 2 (12.5%) 6 (40.0%) —
Retired 2 (5.9%) — — —
Not employed 6 (17.6%) 14 (87.5%) 2 (13.3%) 9 (100.0%)
Ethnic group:
White (Non-Hispanic) 19 (55.9%) 8 (50.0%) 12 (80.0%) 5 (55.6%)
Black/African American 12 (35.3%) 4 (25.0%) 1 (6.7%) —
Asian/Pacific Islander 1 (2.9%) 2 (12.5%) 2 (13.3%) —
Hispanic/Latino 2 (5.9%) 2 (12.5%) — 4 (44.4%)
*Highest level for adults; current level for adolescents.
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Asthma symptoms
The most frequently reported symptoms in the adult
population were chest tightness (n = 33/34; 97.1% of pa-
tients reporting this symptom), wheezing (n = 31; 91.2%),
coughing (n = 30; 88.2%), and shortness of breath (n =
25; 73.5%). In adolescent subjects, wheezing (n = 14/16;
87.5%), coughing (n = 13; 81.3%), chest tightness (n = 11;
68.8%), and fatigue (n = 9; 56.3%) were the most
frequently reported symptoms. The most difficult symp-
toms of asthma were shortness of breath (mean rank =
7.2), followed by chest tightness, coughing, and wheez-
ing (6.7, 6.3, and 6.0, respectively). The severity scores
rate the severity of each symptom on a 10-point NRS
and indicate that chest tightness (mean score = 7.6),
shortness of breath, coughing, and wheezing (mean
scores of 7.3, 7.0, and 7.0, respectively) were the most in-
tensely experienced symptoms by adults and also re-
ported to be among the most important symptoms to
alleviate. The adolescent group’s most difficult reportedsymptom was fatigue (mean rank = 7.4), followed by chest
tightness, wheezing, and coughing (6.6, 6.5, and 6.3, re-
spectively). For adolescents, the most severe symptoms
were coughing and chest tightness (mean rating = 6.9
for both), followed by fatigue, shortness of breath, and
wheezing (6.7, 6.6, and 6.6, respectively).
Markers of symptom severity in asthma
The two most frequently reported symptom-related clin-
ical manifestations (markers of symptom severity as en-
dorsed by GINA), were physical activities (adult, n = 25
spontaneous mentions; adolescent, n = 12 spontaneous
mentions) and sleep disruption (adult, n = 14 spontan-
eous mentions; adolescent, n = 8 spontaneous mentions).
Variations – age and timing
While activity limitation for adolescents tended to focus
more on physical activities tied to school, and adults
tended to speak more about restrictions in activities
commonly engaged in as a part of their daily life, both
Table 2 Clinical characteristics of study subjects
Concept elicitation interviews Cognitive interviews
Parameter Adult N = 34 (100%) Adolescent N = 16 (100%) Adult N = 15 (100%) Adolescent N = 9 (100%)
Atopic status
Allergic 27 (79.4%) 16 (100.0%) 10 (66.7%) 9 (100.0%)
Non-allergic 5 (14.7%) — 4 (26.7%) –
Missing 2 (5.9%) — 1 (6.7%) –
FEV1 predicted:
>95% 3 (8.8%) 8 (50.0%) 4 (26.7%) 2 (22.2%)
95%–90% 3 (8.8%) 2 (12.5%) 1 (6.7%) 2 (22.2%)
89%–80% 10 (29.4%) 5 (31.3%) 2 (13.3%) 3 (33.3%)
79%–70% 9 (26.5%) — 5 (33.3%) 2 (22.2%)
69%–60% 4 (11.8%) 1 (6.3%) 2 (13.3%) —
59%–50% 3 (8.8%) — 1 (6.7%) —
<50% 2 (5.9%) — — —
ACQ scores Adult N = 34 (100%) Adolescent N = 16 (100%) Adult N = 15 (100%) Adolescent N = 9 (100%)
ACQ score categories:
ACQ score ≥3 (severe group) 7 (20.6%) 5 (31.3%) 3 (20.0%) 1 (11.1%)
ACQ score ≥1.5 to < 3 (moderate group) 23 (67.6%) 10 (62.5%) 9 (60.0%) 6 (66.7%)
ACQ score ≥0.5 to <1.5 to (mild group) 4 (11.8%) 1 (6.3%) 3 (20.0%) 2 (22.2%)
ACQ mean score:
Mean (SD) 2.1 (0.74) 1.7 (0.63) 2.1 (0.80) 2.3 (0.90%)
AQLQ: Overall score Adult N = 34 (100%) Adolescent N = 16 (100%) Adult N = 15 (100%) Adolescent N = 9 (100%)
Mean (SD) 4.8 (1.2) 5.0 (0.8) 4.8 (1.0) 5.0 (1.1)
Median 4.9 5.2 4.8 5.3
Range 2-7 4-7 3-7 3-6
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for the activities and the degrees of restriction they
experienced. For example, adolescent subjects used
different reference for their activities (i.e., physical
education class versus the adults’ expression of exer-
cising at the gym). Even though adult and adolescent




Breathing difficulties 18 8 7
Wheezing 9 4 13
Coughing 6 3 12
Chest discomfort 13 3 8
Tiredness 4 2 1
Dizziness and lightheadedness 2 1 0
Allergic symptoms 0 0 1
Throat closing 0 0 1
*Table reflects the number of participants who indicated whether symptom frequenfocus in both age groups was on the same aspect of re-
striction and impairment.
During the concept elicitation interviews, subjects
were asked to describe whether they experienced each
symptom more often or with more severity during the
day or at night. Table 3 shows a breakdown of subject
expressions regarding whether they experienced specifictom expressions of frequency and severity*
Most severe
Day Night
Adolescents Adults Adolescents Adults Adolescents
2 13 6 6 3
4 7 1 9 8
6 7 1 7 6
6 8 1 9 5
0 5 2 0 0
0 0 1 0 1
0 1 0 0 0
1 0 0 0 0
cy and symptom severity was worse during the day or night.
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day or night. It can be seen that subjects spoke about ex-
periencing certain symptoms, such as breathing difficul-
ties, more often and more severely during the day and
some as more often and more severely at night (such as
chest discomfort or wheezing).
Saturation of concepts was achieved in both adult and
adolescent study population subgroups by the end of the
third transcript group, with no new concepts elicited
from the last interviews in the study sample.
After extensive review of the data and discussion at
the item generation meeting, the following points and
modifications were agreed upon:Decisions made based on the concept elicitation and
supported by the literature
 The four asthma symptoms that appeared to be the
most relevant to patients included shortness of
breath, chest tightness, coughing, and wheezing.
These were selected for inclusion in the diary as
specific symptom items. Night awakenings and
activity limitations (considered symptom-related
clinical manifestations by GINA, also referred to as
markers of symptom severity) were the two most
frequently reported impacts among both adolescents
and adults and these were retained as well. Based
upon the qualitative evidence as well as clinical and
PRO expert opinion, no new items needed to be
added to the ASD.
 Severity was reported by patients as the most logical
aspect to be asked about when they reported their
symptoms. Questions stems were changed to
specifically ask patients to report on the severity
of their symptoms rather than simply rate their
symptoms and rely on the response option to
sufficiently carry the message of what they were
being asked to think about.
 It was agreed that a 5-point ordinal severity scale
(no symptom to very severe) should replace the
original 4-point scale for all items in the ASD to
better capture the range of symptom severity.
 The qualitative evidence indicated that symptom
severity differed between night and day. Therefore
it was determined that the same symptom items
should be added to the morning diary.Decisions based on cognitive interviews
The results of initial two waves of cognitive interviews
highlighted the need to make several relatively minor
modifications. For example, items with duration as a re-
sponse, symbols used to indicate more than or less than
were replaced with full wording to improve clarity.At the conclusion of wave 3, patients reported finding
the measure understandable, relevant to their experi-
ence, and easy to complete. The response options were
endorsed as understandable and matching the item stem
by the end of the third wave of interviews.
The final revised ASD is an 11-item measure that is
comprised of 6 items from the morning diary and 5
items from the evening diary. The morning diary items
include questions about the severity of wheezing, short-
ness of breath, cough, chest tightness, and the presence
and duration of nighttime awakenings. The evening
diary items include questions about the severity of
wheezing, shortness of breath, cough, chest tightness,
and activity limitation.
In addition to the 11 ASD items (Table 4; 9 symptoms
and 2 markers of symptom severity) described above,
there are an additional 10 items that are not a scored
part of the ASD but provide important clinical informa-
tion on the patient status alongside symptom severity.
These additional 10 items (5 morning and 5 evening)
ask about the use of asthma rescue medication. The res-
cue medication-related questions cover the frequency of
rescue inhaler or nebulizer use. The rescue medication
questions are not part of the ASD score or 7-day average
ASD symptom severity score. The rescue medication
questions are summarized in a separate daily and weekly
rescue medication score.
Discussion
This qualitative research identifies a set of symptoms
and markers of symptom severity that are relevant to the
experience of patients who have asthma. The most rele-
vant symptoms identified in both the adult and adoles-
cent populations included chest tightness, wheezing,
coughing, and shortness of breath. These symptoms,
identified in the qualitative research, are consistent with
the core asthma symptoms identified in the literature
[5,18]. Among impacts that are considered to be
markers of symptom severity, limitations in physical
activities and sleep disruption were identified in this
qualitative research study as being most difficult for
patients to cope with. The decision to include these
two markers of symptom severity in the ASD was sup-
ported by both the qualitative research (patient spon-
taneous self-report) as well as the literature [8,18],
which indicates that physical activity and sleep prob-
lems feature prominently in asthma. Although activity
limitations and sleep disturbances might also be con-
sidered as assessing impact, the study team, influenced
by the weight of the evidence in the literature, theo-
rized that, in the case of asthma, symptom severity may
be expressed in terms of their impact. The study team
conceptualized that one or more markers of symptom
severity could be so interrelated to symptoms that they
Table 4 ASD Items
ASD items 5 Item response range
Morning (AM)
AM 1 Wheezing None – Very severe
AM 2 Shortness of breath None – Very severe
AM 3 Cough None – Very severe
AM 4 Chest Tightness None – Very severe
AM 5 Nighttime awakenings Zero – Unable to sleep
AM 6
Length of time awake Slept through the night – Awake more
than 3 hours
Evening (PM)
PM 6 Wheezing None – Very severe
PM 7 Shortness of breath None – Very severe
PM 8 Cough None – Very severe
PM 9 Chest tightness None – Very severe
PM 10 Activity limitations Not at all – Extremely
ASD = Asthma symptom diary.
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indicator of asthma symptom severity is interference
with sleep and activity limitation. Although these
could be considered impacts rather than symptoms
per se, they were included as well-established markers
of symptom severity, and were endorsed during the
qualitative phase and confirmed during the quantita-
tive phase.
Fatigue was another symptom raised in the interviews
but it was decided by the team of clinician and PRO
experts not to include it as it was posited that it may be
a symptom that is not be solely attributable to asthma.
Because asthma symptoms frequently vary within a 24-
hour period, the team decided to include symptoms in
both the morning and evening ASD to accurately cap-
ture this variation. During the development process, the
ASD item wording was revised to ensure that the items
were understandable to patients with lower reading
levels, as well as to adolescents. Consideration was
also given to selecting language usage that was easily
translatable.
The ASD is a newly developed PRO intended for use
in clinical trials to support labeling claims. The ASD was
developed in line with FDA guidance in terms of content
validity in a population similar to the clinical trial
population, and includes evidences to support concept
relevance, saturation of concept, and appropriate un-
derstanding of the concepts presented on the part of
the patient. The ASD content, structure, and relevance
to intended measurement strategy for assessing the se-
verity of asthma symptoms is supported by input from
qualitative interviews with patients, consultation and
revision by clinical experts, by asthma literature, and
by PRO experts.It is important to note the considerable overlap be-
tween the markers of symptom severity of asthma as
defined by GINA (symptoms, sleep disturbances, limi-
tations of daily activity, impairment of lung function,
and use of rescue medications) and those identified by
participants in this qualitative research. As there are
established clinical measures for assessing lung function,
this aspect was not explored for inclusion in the ASD;
however, all other aspects of asthma, as contemplated by
GINA, emerged in the qualitative subject interviews and,
in addition to the clinical endorsement of these symptoms
throughout the development process, add support to the
content validity of the ASD.
Traditionally the assessment of asthma has included
clinical factors such as lung function and exacerbation
rates. Patient-reported and clinical composite measures
have also been used to assess the patient experience al-
though none presently meet the rigorous standards
reflected by current FDA guidance [15]. This together
with the evidence that lung function [7] and clinician re-
ported severity [11-13] do not necessarily reflect a pa-
tient’s experience of asthma and highlights the need for
a more accurate assessment of asthma outcomes. Mov-
ing forward, in accordance with recent consensus rec-
ommendations [4,5,22], if studies are to accurately assess
treatment options, then they need to accurately assess
multiple asthma outcomes. Symptoms are one of the key
elements that require attention and this need is reiter-
ated in the review by Krishnan et al. [14] which did
not find a single measure suitable for recommendation
as a “core” symptom measure. Thus, the development
of a patient-reported symptom diary, with docu-
mented content validity, serves an important need; to
obtain the patients’ perspective on treatment out-
comes that are not presently accurately captured in
other endpoint assessments.
Qualitative research confirmed the overall content of
the original clinician developed ASD. Expert clinicians
reviewing the qualitative results agreed that there were
no additional asthma symptoms that needed to be added
to the diary. Refinements to item language and response
items were based upon the results of the qualitative re-
search with patients in conjunction with significant in-
put from clinicians and PRO experts. The similar
manner in which both adults and adolescents reported
and understood their experiences suggested that one sin-
gle measure for use in both groups was found to be ap-
propriate. As there was a clear distinction between day
and night symptoms for both groups, it was determined
that the diary should be administered twice in a 24-hour
period—once upon awakening in the morning and once
prior to retiring to bed in the evening.
The ASD consists of a single domain assessed twice-
daily via an electronic device. The ASD has documented
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asthma patients. This qualitative research study was per-
formed in line with the recommendations in the FDA
PRO Guidance. Evaluation of cross-sectional measure-
ment properties has been completed, further confirming
unidimensionality (by factor analysis) and content valid-
ity (by Rasch analysis), and will be reported in detail in a
separate publication.
Conclusions
The development of the ASD was in line with recom-
mendations in the FDA PRO Guidance document, with
key input from patients, clinicians and the literature.
Revisions were made during the development process
based on patient responses, clinical advice and expertise
in the development of PROs. Patients included in this
research reflected a diverse asthma population in terms
of disease control, gender, age (both adults and adoles-
cents), education, ethnicity, and socioeconomic status
mirroring the general asthma population as well as the
intended trial population of adults and adolescents with
persistent asthma. In the concept elicitation interviews
concept saturation and content validity was confirmed.
The outcome of this study suggests that the ASD has
demonstrated content validity. The resulting 11-item
morning and 10-item evening diary assessing asthma
symptoms and markers of symptom severity, instruc-
tions, and response options are well understood and
relevant as verified by patients with asthma. This study
supports the content validity of the revised ASD, show-
ing it to be consistent with patient experiences and
ready for further psychometric testing. The results of the
quantitative assessment of the psychometric properties
of the revised ASD are reported elsewhere.
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